Is there an alternative to ibrutinib?

This finding suggests that acalabrutinib is a well-tolerated alternative for patients who have developed an intolerance to ibrutinib, says Leslie.

Is acalabrutinib better than ibrutinib?

Abstract. Purpose: Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability.

Is Calquence better than ibrutinib?

Acalabrutinib (Calquence) was found to have a lower incidence of cardiovascular-related toxicities and a lower toxicity burden compared with ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL), according to John Seymour, MD, who added that because of these data, the former BTK inhibitor may be the ...

Is acalabrutinib the same as ibrutinib?

The way that both acalabrutinib and ibrutinib work is by irreversibly binding to and destroying the cancerous B lymphocytes. Acalabrutinib's increased selectivity means that the risk of off-target cells, or noncancerous cells, is much lower than in ibrutinib, which thus results in a lower risk of adverse effects.

Can you switch from ibrutinib to acalabrutinib?

After ibrutinib discontinuation, the median time from taking the last dose of ibrutinib to starting acalabrutinib was 7.5 months (range, 0.8-31.1). At a median follow-up of 34.6 months (range, 1.1-47.4), 29 (48%) patients remained on acalabrutinib; 45 patients (75%) had at least 1 year of treatment.

Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?

What happens when ibrutinib stops working?

Stopping ibrutinib can result in a disease flare-up in patients with chronic lymphocytic leukemia (CLL). A 2020 study in The Oncologist found that approximately 25% of ibrutinib patients with a median interruption period of 8 days experienced a flare or rapid CLL progression.

What are the latest treatments for CLL?

In May 2019, the FDA approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) to treat people with previously untreated CLL as a chemotherapy-free option. In April 2020, the FDA approved a combination therapy of rituximab (Rituxan) and ibrutinib (Imbruvica) for adult patients with chronic CLL.

Is Zanubrutinib better than ibrutinib?

“Zanubrutinib was also superior to ibrutinib in terms of progression-free survival,” he further reported. The 12-month landmark event-free rates for zanubrutinib vs ibrutinib were 94.9% vs 84.0%, respectively (HR = 0.40; P = . 0007).

What is the difference between ibrutinib and Imbruvica?

Imbruvica™ is the trade name for the generic drug ibrutinib. In some cases, health care professionals may use the generic name ibrutinib when referring to the trade name Imbruvica™.

How effective is ibrutinib?

In December, O'Brien reported on a clinical trial involving 140 CLL patients that showed ibrutinib alone produces complete or partial responses in 88% of those who have had previous treatment, and 86% who have received the drug as initial therapy.

Is Calquence cheaper than Imbruvica?

Calquence charges about $170,000/ year (WAC price) compared to Imbruvica's $157,000. Given its level of clinical benefit, it is appropriately priced.

Can Imbruvica cure CLL?

Imbruvica Improves Outcomes in CLL, But Less Toxic Treatments Still Needed. Regimens containing Imbruvica bested chemoimmunotherapy treatments in elderly patients with chronic lymphocytic leukemia, but less toxic and long-term treatments are still needed.

In what country is Imbruvica made?

The Pharmacyclics name was retained, and it operates as a subsidiary of AbbVie from its previous Sunnyvale, California, headquarters. Janssen markets Imbruvica in Europe, the Middle East and Africa and AbbVie markets it in the United States.

Is acalabrutinib approved for CLL?

Treatment with acalabrutinib is already approved for use in patients with CLL. Since ibrutinib is not always tolerated well by patients, acalabrutinib has positioned itself as an effective alternative treatment option.

Can ibrutinib cause kidney failure?

Despite the fact that less than 10% of ibrutinib is excreted by kidneys, increase in creatinine level 1.5 to 3 times the upper limit of normal occurs in up to 9% of patients during treatment⁴ and occasionally patients were developed serious renal failure.

What are the side effects of acalabrutinib?

How long can you live taking Imbruvica?

The average duration of Imbruvica therapy in clinical trials has been around 41 months (range, 2–51 months). In people who have stopped Imbruvica, the average survival after treatment discontinuation was 8 months.

Is ibrutinib a form of chemo?

Ibrutinib is not a chemotherapy drug but one of what are termed "targeted therapies." Targeted therapy is the result of years of research dedicated to understanding the differences between cancer cells and normal cells.

Is there a generic for Imbruvica?

No. There is currently no therapeutically equivalent version of Imbruvica available in the United States. Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Imbruvica. These medications may be counterfeit and potentially unsafe.

How much does zanubrutinib cost?

On Friday, BeiGene priced its drug zanubrutinib (Brukinsa), a mantle cell lymphoma (MCL) treatment, at $12,935 for a 30-day supply, Reuters reported. According to the article, the FDA on Thursday granted accelerated approval to zanubrutinib for adult patients with previously-treated MCL.

Is zanubrutinib approved for CLL?

The FDA has accepted a supplemental new drug application for zanubrutinib (Brukinsa, BeiGene) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.

Does Imbruvica cause heart problems?

IMBRUVICA® may cause serious side effects, including bleeding problems (hemorrhage), infections, decrease in blood cell counts, heart problems: serious heart rhythm problems (ventricular arrhythmias, atrial fibrillation, and atrial flutter) and heart failure, high blood pressure (hypertension), second primary cancers, ...

Can you live 20 years with CLL?

CLL has a very high incidence rate in people older than 60 years. CLL affects men more than women. If the disease has affected the B cells, the person's life expectancy can range from 10 to 20 years.

How do you know if CLL is getting worse?

Unexplained weight loss of more than 10 percent of your body weight over the course of 6 months or so could mean your CLL is progressing. This means that you're losing weight when you're not trying to diet.

Are they working on a cure for CLL?

As of now, no treatment can cure CLL. The closest thing we have to a cure is a stem cell transplant, which is risky and only helps some people survive longer. New treatments in development could change the future for people with CLL. Immunotherapies and other new drugs are already extending survival.